Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-03: ctDNA-Guided Adjuvant Therapy in Colorectal Cancer
NCT07562503Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Capecitabine + oxaliplatin, FOLFOX, FOLFIRI in colorectal cancer (CRC), sponsored by Fudan University. Started Nov 2024; status: recruiting.
02
Drugs
Capecitabine + oxaliplatinFOLFOXFOLFIRI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07562503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562503.